The Saudi Food and Drug Authority (SFDA) is participating in the global pharmaceutical exhibition, the Convention on Pharmaceutical Ingredients (CPHI) Middle East, sponsored and supported by the Saudi Ministry of Health. The event will be held at the Riyadh Exhibition and Convention Center from December 10 to 12, 2024, featuring participation from over 100 countries, 150 speakers, and 400 exhibitors representing major local and international pharmaceutical companies.

During its participation, the SFDA highlighted its role as a strategic partner with researchers and manufacturers to accelerate the adoption of innovative medicines and technologies while ensuring product safety and quality. This aligns with the Saudi Vision 2030, which aims to expand economic horizons by empowering the pharmaceutical industry, supporting biotechnology, and fostering innovation.

In this context, the SFDA has worked to enhance the availability of innovative medicines through the "Breakthrough Medicines Program," which expedites product registration. The Authority is also committed to improving the investment environment in this sector and supporting local production of medicines and innovative products.

The SFDA pavilion showcased its key initiatives and future projects aimed at improving the efficiency of the pharmaceutical supply chain, electronic services for the pharmaceutical sector, and regulatory procedures for medicine and medical preparation registration. Additionally, the participation will include awareness sessions for specialists and local and international companies to inform them about the Authority's requirements and its role in supporting the pharmaceutical industry.

As the largest pharmaceutical event in the Middle East, this exhibition provides a platform for major local and international pharmaceutical companies to focus on innovation and enhance global partnerships in the health sector, contributing to a sustainable and healthy future.